Ert Pompe denied as experimental or investigational by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for ert pompe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS May Deny ERT for Pompe Disease as "Experimental or Investigational"

A denial categorizing enzyme replacement therapy (ERT) for Pompe disease as experimental or investigational is one of the more legally vulnerable denial types a Blue Cross Blue Shield plan can issue for this indication. ERT for Pompe disease has held FDA approval, and the condition is recognized in specialist-society guidelines as an indication for which ERT is the established standard of care. Denials on experimental grounds typically occur when an older plan policy has not been updated, when a newly approved or recently expanded ERT product is being evaluated under an outdated policy, or — rarely — when the specific patient presentation differs from the approved label indication.

## Why This Denial Is Appealable

FDA approval establishes that a drug is not experimental for its approved indication. BCBS's own coverage policy for most regulated plans requires them to cover FDA-approved drugs used for FDA-approved indications. If the denial cannot point to a specific, documented reason why this patient's use falls outside the approved label, it is reversible.

## Federal Appeal Framework

• Internal appeal: File within the deadline on your denial letter. For a denial that affects ongoing treatment of a serious progressive disease, document clinical urgency and request expedited review (72-hour turnaround).
• External review (ACA §2719): "Experimental or investigational" denials are among the clearest grounds for external review. The IRO will assess whether the denial is consistent with generally accepted medical standards — and FDA approval plus specialist-society consensus is strong evidence that it is not. The external-review window is typically four months from final internal denial.
• ERISA §503 (employer plans): You are entitled to the specific clinical basis for the experimental finding, including any coverage policy version and the credentials of the reviewing clinician.
• State insurance law: Many states prohibit experimental-or-investigational denials for FDA-approved drugs used in their approved indications. Cite your state's applicable statute or regulation in the appeal.

## Documentation to Gather

• FDA approval documentation: The current FDA-approved prescribing label for the specific ERT product, showing the approved indication includes Pompe disease.
• Specialist-society guidelines: A reference (by organization name) to the guideline body that endorses ERT as the recognized standard of care for Pompe disease.
• Treating physician letter: A detailed letter from the prescribing metabolic disease or neuromuscular specialist affirming that ERT for this patient's diagnosis is standard, not investigational, care.
• Diagnosis confirmation: Genetic mutation analysis and/or enzyme assay confirming Pompe disease, to establish that the use is squarely within the FDA-approved indication.
• BCBS coverage policy: Pull the current BCBS medical policy on ERT for Pompe disease and compare the language to the denial rationale — inconsistencies strengthen your appeal.

## Criteria-Mapping Structure

| Experimental-Denial Element | Your Response | |---|---| | Claim: treatment lacks FDA approval | [FDA label for approved indication] | | Claim: lacks generally accepted clinical evidence | [Specialist-society guideline organization + treating physician letter] | | Claim: patient use outside approved label | [Confirmed diagnosis matching approved indication] | | Plan policy version cited in denial | [Compare to current published BCBS policy — note any discrepancy] |

External reviewers overturn experimental-or-investigational denials at high rates when FDA approval and specialist-society consensus are clearly documented. Do not skip external review if the internal appeal is denied.